Patents by Inventor Kentaro Futatsugi

Kentaro Futatsugi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLP-1 Receptor Agonists and Uses Thereof
    Publication number: 20190119255
    Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Application
    Filed: December 14, 2018
    Publication date: April 25, 2019
    Applicant: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, David Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Gajendra Ingle, Wenhua Jiao, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
  • SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITORS
    Publication number: 20190106412
    Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Application
    Filed: December 6, 2018
    Publication date: April 11, 2019
    Applicant: Pfizer Inc.
    Inventors: Matthew Dowling, Dilinie Fernando, Kentaro Futatsugi, Kim Huard, Thomas Victor Magee, Brian Raymer, Andre Shavnya, Aaron Smith, Benjamin Thuma, Andy Tsai, Meihua Tu
  • GLP-1 receptor agonists and uses thereof
    Patent number: 10208019
    Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: February 19, 2019
    Assignee: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, David Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Gajendra Ingle, Wenhua Jiao, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
  • Diacylglycerol acyltransferase 2 inhibitors
    Patent number: 10188653
    Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: January 29, 2019
    Assignee: Pfizer Inc.
    Inventor: Kentaro Futatsugi
  • Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
    Patent number: 10174007
    Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: January 8, 2019
    Assignee: Pfizer Inc.
    Inventors: Matthew Dowling, Dilinie Fernando, Kentaro Futatsugi, Kim Huard, Thomas Victor Magee, Brian Raymer, Andre Shavnya, Aaron Smith, Benjamin Thuma, Andy Tsai, Meihua Tu
  • DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITORS
    Publication number: 20180258081
    Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Application
    Filed: May 11, 2018
    Publication date: September 13, 2018
    Applicant: Pfizer Inc.
    Inventors: Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
  • Diacylglycerol acyl transferase 2 inhibitors
    Patent number: 10071992
    Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: September 11, 2018
    Assignee: Pfizer Inc.
    Inventors: Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
  • GLP-1 Agonists and Uses Thereof
    Publication number: 20180170908
    Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Application
    Filed: December 13, 2017
    Publication date: June 21, 2018
    Applicant: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, David Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Gajendra Ingle, Wenhua Jiao, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
  • DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITORS
    Publication number: 20180051012
    Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Application
    Filed: August 11, 2017
    Publication date: February 22, 2018
    Applicant: Pfizer Inc.
    Inventors: Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
  • DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS
    Publication number: 20180042926
    Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Application
    Filed: September 1, 2017
    Publication date: February 15, 2018
    Applicant: Pfizer Inc.
    Inventor: Kentaro Futatsugi
  • SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITORS
    Publication number: 20180037575
    Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Application
    Filed: October 11, 2017
    Publication date: February 8, 2018
    Inventors: Matthew Dowling, Dilinie Fernando, Kentaro Futatsugi, Kim Huard, Thomas Victor Magee, Brian Raymer, Andre Shavnya, Aaron Smith, Benjamin Thuma, Andy Tsai, Meihua Tu
  • Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
    Patent number: 9809579
    Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: November 7, 2017
    Assignee: Pfizer Inc.
    Inventors: Matthew Dowling, Dilinie Fernando, Kentaro Futatsugi, Kim Huard, Thomas Victor Magee, Brian Raymer, Andre Shavnya, Aaron Smith, Benjamin Thuma, Andy Tsai, Meihua Tu
  • Diacylglycerol acyltransferase 2 inhibitors
    Patent number: 9789110
    Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: October 17, 2017
    Assignee: Pfizer Inc.
    Inventor: Kentaro Futatsugi
  • Antagonists of prostaglandin EP3 receptor
    Patent number: 9738626
    Abstract: Provided herein are antagonists of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: August 22, 2017
    Assignee: Pfizer Inc.
    Inventors: Kevin Bahnck, Daniel Canterbury, David James Edmonds, Kentaro Futatsugi, Esther Cheng Yin Lee, Elnaz Menhaji-Klotz, Jana Polivkova, Robert Vernon Stanton
  • SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITORS
    Publication number: 20170183328
    Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Application
    Filed: December 16, 2016
    Publication date: June 29, 2017
    Inventors: Matthew Dowling, Dilinie Fernando, Kentaro Futatsugi, Kim Huard, Thomas Victor Magee, Brian Raymer, Andre Shavnya, Aaron Smith, Benjamin Thuma, Andy Tsai, Meihua Tu
  • DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS
    Publication number: 20160303125
    Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Application
    Filed: June 27, 2016
    Publication date: October 20, 2016
    Applicant: PFIZER INC.
    Inventors: SHAWN CABRAL, KENTARO FUTATSUGI, DAVID HEPWORTH, KIM HUARD, DANIEL WEI-SHUNG KUNG, SUVI TUULA MARJUKKA ORR, KUN SONG
  • Diacylglycerol acyltransferase 2 inhibitors
    Patent number: 9440949
    Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: September 13, 2016
    Assignee: Pfizer Inc.
    Inventors: Shawn Cabral, Kentaro Futatsugi, David Hepworth, Kim Huard, Daniel Wei-Shung Kung, Suvi Tuula Marjukka Orr, Kun Song
  • ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR
    Publication number: 20160176851
    Abstract: Provided herein are antagonists of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 23, 2016
    Applicant: Pfizer Inc.
    Inventors: Kevin Bahnck, Daniel Canterbury, David James Edmonds, Kentaro Futatsugi, Esther Cheng Yin Lee, Elnaz Menhaji-Klotz, Jana Polivkova, Robert Vernon Stanton
  • Diacylglycerol acyltransferase 2 inhibitors
    Patent number: 9296745
    Abstract: Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Grant
    Filed: March 26, 2013
    Date of Patent: March 29, 2016
    Assignee: Pfizer Inc.
    Inventors: Kay Ahn, Markus Boehm, Shawn Cabral, Philip A. Carpino, Kentaro Futatsugi, David Hepworth, Daniel W. Kung, Suvi Orr, Jian Wang
  • Antagonists of prostaglandin EP3 receptor
    Patent number: 9278953
    Abstract: Provided herein are antagonists of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: March 8, 2016
    Assignee: Pfizer Inc.
    Inventors: Kevin Barry Bahnck, David James Edmonds, Kentaro Futatsugi, Esther Cheng Yin Lee, Alan Martin Mathiowetz, Elnaz Menhaji-Klotz, Robert Vernon Stanton